What is LENSAR?
LENSAR, Inc. is a specialized medical technology firm headquartered in Orlando, Florida, dedicated to advancing refractive eye surgery through its innovative robotic cataract laser systems. The company's core mission revolves around developing cutting-edge solutions designed to enhance precision, safety, and patient outcomes for surgeons. By integrating advanced technology with a patient-centric philosophy, LENSAR aims to redefine the standards of modern cataract surgery, offering a transformative approach to vision correction.
How much funding has LENSAR raised?
LENSAR has raised a total of $154.4M across 6 funding rounds:
Other Financing Round
$24M
Multiple Rounds
$114.4M
Unspecified
$16M
Other Financing Round (2012): $24M with participation from Aisling Capital and Florida Growth Fund
Unspecified (2013): $17.4M, investors not publicly disclosed
Private Equity (2013): $27M supported by PDL Biopharma, Florida Opportunity Fund, Aisling Capital, and Florida Growth Fund
Debt (2013): $60M featuring PDL BioPharma, Inc.
Private Equity (2013): $10M, investors not publicly disclosed
Unspecified (2015): $16M with participation from Undisclosed
Key Investors in LENSAR
Aisling Capital
Aisling Capital is a venture capital firm that specializes in investing in companies developing innovative healthcare products and technologies. Their focus spans biopharmaceutical development and commercial outsourcing, targeting areas like oncology and neuroscience.
Florida Growth Fund
Florida Growth Fund is an investment firm that supports early-stage companies to bolster Florida's innovation economy. They invest in sectors such as technology and life sciences, aiming to foster long-term growth and capital appreciation.
PDL BioPharma, Inc.
PDL BioPharma manages a portfolio of patents and royalty assets, licensing them to biotechnology and pharmaceutical companies. Their business model focuses on leveraging intellectual property in the life sciences sector.
What's next for LENSAR?
With the recent major strategic investment and a history of substantial enterprise-level funding, LENSAR is well-positioned for accelerated growth and market penetration. The company's focus on robotic laser systems for cataract surgery aligns with the increasing demand for minimally invasive and highly accurate ophthalmic procedures. Future developments are likely to concentrate on enhancing the capabilities of their existing platforms, expanding their product portfolio, and broadening their global reach. This strategic financing will undoubtedly support LENSAR's ongoing commitment to innovation and its objective of becoming a leader in the ophthalmic technology landscape.
See full LENSAR company page
